Brachytherapy helps maintain erectile function in prostate cancer patients without compromising treatment outcomes
The use of permanent brachytherapy, a procedure where radioactive sources are placed inside the prostate, into or near to the tumor, preserves erectile function in approximately 50% of patients with prostate cancer. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 5, 2014 Category: Science Source Type: news
Cianna touts breast brachytherapy results
Cianna Medical is highlighting results of a retrospective study of breast cancer (more) (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 4, 2014 Category: Radiology Source Type: news
Brachytherapy helps maintain erectile function in prostate cancer patients without compromising treatment outcomes
(European Society for Radiotherapy and Oncology (ESTRO)) The use of permanent brachytherapy, a procedure where radioactive sources are placed inside the prostate, into or near to the tumour, preserves erectile function in approximately 50 percent of patients with prostate cancer. Brachytherapy used alone is as effective as other established therapies for localized low to intermediate risk prostate cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 4, 2014 Category: Cancer & Oncology Source Type: news
IsoRay Announces World's First Pediatric Cesium-131 Seeded Mesh Treatment for Metastatic Wilms Tumor
Cesium-131 Implants Used to Provide Needed Radiation to Treat This Aggressive Cancer
RICHLAND, WA--(Healthcare Sales & Marketing Network) - IsoRay Inc. (NYSE MKT: ISR) (http://www.isoray.com/), a medical technology company and innovator in seed brachyth... Devices, OncologyIsoRay, brachytherapy, Cesium-131, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 19, 2014 Category: Pharmaceuticals Source Type: news
First US patients receive Esteya electronic brachytherapy for skin cancer
Patient-friendly treatment helps minimize radiation exposure to healthy tissues
LOS GATOS, Calif., March 5, 2014 -- (Healthcare Sales & Marketing Network) -- On January 14, a 67-year-old male patient received his final Esteya® electronic brachyther... Devices, OncologyElekta, Esteya, electronic brachytherapy, brachytherapy, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 5, 2014 Category: Pharmaceuticals Source Type: news
Guidance for optimal quality, safety of HDR brachytherapy
A new white paper has been issued that recommends specific guidance to follow in the delivery of high-dose-rate brachytherapy to improve quality and patient safety. To ensure correct actions are followed for a specific brachytherapy procedure, the white paper recommends the use of a quality management program, including checklists and forms to maintain quality and prevent errors. Also, due to the multidisciplinary nature of HDR brachytherapy treatment, the modality requires coordination among several clinicians to treat the patient accurately and safely. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 5, 2014 Category: Science Source Type: news
ASTRO white paper provides guidance for optimal quality, safety of HDR brachytherapy
(American Society for Radiation Oncology) The American Society for Radiation Oncology (ASTRO) has issued a new white paper, "A review of safety, quality management, and practice guidelines for high-dose-rate brachytherapy," that recommends specific guidance to follow in the delivery of high-dose-rate brachytherapy to improve quality and patient safety, according to the manuscript published in the March-April 2014 print issue of Practical Radiation Oncology, the official clinical practice journal of ASTRO. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 5, 2014 Category: Global & Universal Source Type: news
MammoSite Breast Brachytherapy
MammoSite breast brachytherapy is an alternative radiation treatment to external beam radiation of the breast. MammoSite breast brachytherapy takes 5 days to completely treat early stage breast cancer with radiation after a lumpectomy. Learn more about MammoSite breast brachytherapy here. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - February 28, 2014 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news
AMIC looks to down-classify brachytherapy's FDA status
Advanced Medical Isotope Corp. considers pursuing regulatory down-classification for its brachytherapy cancer product.
Washington-based Advanced Medical Isotope Corp. is evaluating its options for U.S. market approval of its proprietary brachytherapy cancer product, the company announced.
Advanced Medical Isotope Corp., Food & Drug Administration (FDA)News Well, Regulatory/Clearance, Brachytherapy, Food & Drug Administration (FDA), Oncology, Pre-Market Approval (PMA), Radiosurgeryread more (Source: Mass Device)
Source: Mass Device - February 24, 2014 Category: Medical Equipment Authors: Arezu Sarvestani Source Type: news
Mixed Results for Brachytherapy in Breast Cancer (CME/CE)
(MedPage Today) -- Older breast cancer patients had an increased rate of subsequent mastectomy if they received brachytherapy instead of external-beam radiation therapy after lumpectomy but fared better than patients who received no radiation, investigators reported. (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - February 7, 2014 Category: Surgery Source Type: news
Study finds brachytherapy offers lower rate of breast preservation compared to standard radiation for older women with breast cancer
When comparing treatments designed to enable long-term breast preservation for older women with invasive breast cancer, researchers found those treated with brachytherapy were at higher risk for a later mastectomy, compared to women treated with standard radiation therapy. The research was led by The University of Texas MD Anderson Cancer Center. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - February 5, 2014 Category: Cancer & Oncology Source Type: news
Study finds brachytherapy offers lower rate of breast preservation compared to standard radiation for older women with breast cancer
(University of Texas M. D. Anderson Cancer Center) When comparing treatments designed to enable long-term breast preservation for older women with invasive breast cancer, researchers found those treated with brachytherapy were at higher risk for a later mastectomy, compared to women treated with standard radiation therapy. The research was led by The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 30, 2014 Category: Cancer & Oncology Source Type: news
Estro 33
(European Society for Radiotherapy and Oncology (ESTRO)) What is ESTRO 33? ESTRO 33 will feature new research results in clinical radiation oncology, radiobiology, physics, technology, and brachytherapy, presented by top doctors and scientists from all over the world working together for the benefit of cancer patients. The conference is expected to attract 3700 delegates from more than 80 countries. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 30, 2014 Category: Cancer & Oncology Source Type: news
EBRT reduces risk of subsequent mastectomy in patients with invasive breast cancer
(American Society for Radiation Oncology) Standard external beam radiation therapy (EBRT) provided a higher breast preservation rate than brachytherapy in women age 66 and older with invasive breast cancer, according to a study published in the Feb. 1, 2014, print edition of the International Journal of Radiation Oncology*Biology*Physics, the official scientific journal of the American Society for Radiation Oncology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 29, 2014 Category: Cancer & Oncology Source Type: news
iCAD announces positive three-year data using the Xoft System to treat skin cancer
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, has announced that positive data using the Company's Xoft® Axxent®Electronic Brachytherapy System® to treat non-melanoma skin cancer (NMSC) were presented at the American Society of Radiation Oncology's (ASTRO) 55th Annual Meeting being held from September 22-25, 2013 in Atlanta... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 27, 2013 Category: Consumer Health News Tags: Melanoma / Skin Cancer Source Type: news
